Related Experiment Video
Updated: Jan 29, 2026

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing
Published on: August 24, 2017
Optimization of Next-Generation Sequencing Technologies for von Hippel Lindau (VHL) Mosaic Mutation Detection and
Lucie Coppin1, Pascal Plouvier2, Michel Crépin2
1UMR-S 1172-Jean-Pierre Aubert Research Center, University of Lille, Lille, France; INSERM, UMR-S 1172, Team on Mucins, Epithelial Differentiation and Carcinogenesis, Lille, France; Department of Biochemistry and Molecular Biology, Centre Hospitalier Régional et Universitaire de Lille, Lille, France.
Abstract:
Von Hippel-Lindau disease (VHL) is a monogenic disorder characterized by the development of tumors affecting the central nervous system, kidney, pancreas, or adrenal glands, and due to germline mutations in the VHL tumor suppressor gene. About 5% of patients with a typical VHL phenotype have no mutation detected by conventional techniques, so a postzygotic VHL mosaicism can be suspected. The aim of this study was therefore to implement a next-generation sequencing (NGS) strategy for VHL mosaic mutation detection, including an optimization of the original Personal Genome Machine design by enrichment with oligonucleotides corresponding to amplicons with insufficient depth of coverage. Two complementary strategies were developed for the confirmation of mosaic mutations identified by NGS, SNaPshot for variants present at an allelic ratio greater than 5%, and droplet digital PCR for allelic ratio above 1%. VHL mutant plasmids were generated to assess VHL mosaic mutation detection in different exons and to set up an internal quality control that could be included in each run or regularly to validate the assay. This strategy was applied to 47 patients with a suggestive or clinical VHL disease, and mosaic mutations were identified in 8.5% of patients. In conclusion, NGS technologies combined with SNaPshot or droplet digital PCR allow the detection and confirmation of mosaic mutations in a clinical laboratory setting.
Insights
Next-generation sequencing effectively detects mosaic mutations in Von Hippel-Lindau (VHL) disease, a genetic disorder causing tumors. This advanced approach improves diagnosis for patients with VHL phenotypes but lacking detectable mutations via conventional methods.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- Von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome caused by germline mutations in the VHL tumor suppressor gene.
- A subset of patients with a VHL phenotype lack detectable mutations using standard genetic testing, suggesting potential mosaicism.
Purpose of the Study:
- To develop and validate a next-generation sequencing (NGS) strategy for detecting VHL mosaic mutations.
- To optimize NGS for improved variant detection sensitivity in VHL mosaicism.
Main Methods:
- Implementation of an optimized NGS strategy with targeted amplicon enrichment.
- Utilized SNaPshot and droplet digital PCR for sensitive confirmation of low-allelic-ratio mosaic mutations.
- Generated VHL mutant plasmids for assay validation and quality control.
Main Results:
- The developed NGS strategy successfully identified mosaic mutations in 8.5% of patients with suspected VHL disease.
- Confirmed mosaic mutations with allelic ratios as low as 1% using droplet digital PCR.
- Established a robust workflow for VHL mosaic mutation detection in a clinical setting.
Conclusions:
- NGS combined with droplet digital PCR and SNaPshot provides a powerful tool for diagnosing VHL mosaicism.
- This approach enhances diagnostic yield in patients with VHL phenotypes but negative conventional genetic testing.
- Enables accurate identification of VHL mosaic mutations, improving patient management and genetic counseling.
Related Concept Videos
The Fluid Mosaic Model
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Next-generation Sequencing
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
Confirmation Biases
Viral Mutations

